Basic Identifiers
| Property | Description |
|---|---|
| Name | Descarboxymethyl Treprostinil |
| CAS Number | 101692-02-8 |
| Category | Pharmaceutical impurity / metabolite / reference standard / intermediate |
Molecular & Physical Data
| Property | Value |
|---|---|
| Molecular Formula | C₂₁H₃₂O₃ |
| Molecular Weight | ≈ 332.48 g/mol |
| Appearance / Physical Form | Supplier listings don’t always specify color or exact appearance. It is supplied as a solid, research standard. |
| Purity | Usually high, but exact % not always disclosed; suppliers treat it as an analytical standard / impurity reference. |
| Storage | 2-8 °C (refrigerated), protected from light and moisture. |
| Shipping Conditions | Often ambient or moderately controlled; some suppliers specify “not human use.” |
Functional / Usage Information
-
Role: Descarboxymethyl Treprostinil is an impurity found in the synthesis of Treprostinil, which itself is a synthetic analog of prostacyclin used to treat pulmonary arterial hypertension.
-
Pharmacological Context: While Treprostinil is an active drug (brand name Remodulin etc.), this compound (Descarboxymethyl Treprostinil) is not a marketed therapeutic agent. It is used for analytical and research purposes (impurity profiling, reference standard for quality control) rather than for medical treatment.
-
Synonyms / IUPAC-like descriptors: One supplier lists a more detailed chemical name: (1R,2R,3aS,9aS)-1-[(3S)-3-Hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalene-2,5-diol.
Key Physical / Stability Features
-
Stability: According to one supplier (RuixiBiotech), the compound’s stability is about 1 year under appropriate storage (cool, protected from light & moisture).
-
Handling: Because it’s an impurity/reference standard, it is handled per standard lab chemical precautions—use gloves, avoid contamination, ensure storage conditions as above. Suppliers usually include an MSDS or COA upon request.
Limitations / Cautions
-
Not approved for therapeutic use. It is explicitly sold only for research / analytical uses.
-
Toxicity / pharmacokinetics data scarce. Being an impurity, detailed pharmacological or toxicological profiles are not generally published.
-
Regulatory implications: As an impurity of Treprostinil, its acceptable limits would be controlled under pharmaceutical quality standards and regulations (e.g. ICH guidelines for impurities). Its presence or quantified amount matters for drug product safety, stability, and regulatory filings.
